A Descriptive Evaluation of Prescriber Perceptions and Experience With Risk Evaluation and Mitigation Strategy (REMS) Programs in an Integrated Health Care System

Abstract

Objective:

To assess prescriber perceptions and experience with risk evaluation and mitigation strategy (REMS) programs in an integrated health care delivery system.

Methods:

A cross-sectional online survey was e-mailed to eligible health care prescribers if they prescribed at least 1 selected REMS-related product within 6 months spanning January 1 to June 30, 2013; were an active employee of Kaiser Permanente Southern California; and had an active “kp.org” e-mail address. Descriptive analyses were conducted on the survey responses.

Results:

Three hundred sixty-four respondents (34%) completed the online survey. The majority were primary care prescribers (65%) versus nonprimary prescribers. The majority of primary care, oncologist, and specialist prescribers responded that REMS was meaningful, improved patient safety, and made an impact on their patient interactions. The majority of surgeons and pain management prescribers responded that REMS was not meaningful, did not improve safety for the patients, or did not impact their interactions with their patients. Over 50% of prescribers counseled their patients or had another health care team member discuss the risks and benefits of these REMS-related medications; medication guides or other printed literature was not provided as much.

Conclusion:

The results from the survey suggest that prescriber specialty has an impact on the perceived value of the REMS program and the perceived need to counsel patients regarding medications with REMS programs.

Keywords

risk evaluation and mitigation strategy (REMS)survey prescribers FDA

Get full access to this article

View all access options for this article.

References

Qato

Alexander

. Improving the Food and Drug Administration’s mandate to ensure postmarketing drug safety. JAMA. 2011;306(15):1595-1596.

Shane

. Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems. Am H Health Syst Pharm. 2009;66:S3-S5.

American Pharmacists Association. APhA 2011 REMS white paper: summary of the REMS stakeholder meeting on improving program design and implementation. J Am Pharm Assoc. 2011;51:340-358.

Craig

. The Food and Drug Administration risk evaluation and mitigation strategy. J Pain Palliat Care Pharmacother. 2010;24:145-148.

US Food and Drug Administration. FDA Basics Webinar: A Brief Overview of Risk Evaluation and Mitigation Strategies (REMS). http://www.fda.gov/aboutfda/transparency/basics/ucm325201.htm. Accessed February 14, 2014.

Center for Drug Evaluation and Research, FDA, Department of Health and Human Services. Risk Evaluation and Mitigation Strategy Assessments: Social Science Methodologies to Access Goals Related to Knowledge. Docket No. FDA-2012-N-0408. June 7, 2012.

US Food and Drug Administration. Public Meeting: Standardizing and Evaluating Risk Evaluation and Mitigation Strategies. http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm351029.htm. Accessed April 24, 2014.

US Food and Drug Administration. Background Materials: REMS Standardization and Evaluation Public Meeting. http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM362078.pdf. Accessed April 24, 2014.

US Department of Health and Human Services, FDA, CDER, CBER. Guidance for Industry: Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications. September 2009: Drug Safety. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM184128.pdf. Accessed December 28, 2014.

10.

Salinas

Robinson

Abdolrasulnia

. Primary care physician attitudes and perceptions of the impact of FDA-proposed REMS policy on prescription of extended-release and long-acting opioids. J Pain Res. 2012;5:363-369.

11.

Slevin

Ashburn

. Primary care physician opinion survey on FDA Opioid Risk Evaluation and Mitigation Strategies. J Opioid Manag. 2011;7(2):109-115.